logo
Plus   Neg
Share
Email

Sorrento Gets FDA Approval For Phase 1 Study For COVID Treatment; Shares Up 5%

Shares of Sorrento Therapeutics Inc. (SRNE) gained over 5% in extended trading session on Tuesday after the company FDA cleared its Investigational New Drug application for early stage study of STI-2099 in both healthy volunteers and COVID-19 patients.

Sorrento Therapeutics said it received clearance from the FDA for its Investigational New Drug application for its Phase 1 study of the safety and pharmacokinetics of intranasal STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.

Sorrento is currently evaluating an intravenous formulation of this potent antibody, STI-2020 (IV), in a Phase 1 study in healthy volunteers and COVID-19 patients with mild symptoms.

"We plan to use our intranasal formulation technology, which allows administering a drug via simple drops in the nose, for other antibodies we are currently developing with a goal of providing coverage against all variants of the SARS-CoV-2 virus that might evade inhibition from treatment with existing therapies," said Dr. Henry Ji, Chairman and CEO of Sorrento.

SRNE closed Tuesday's trading at $9.44, down $0.81 or 7.90%, on the Nasdaq. The stock, however, gained $0.56 or 5.93% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
RELATED NEWS
Follow RTT